866-997-4948(US-Canada Toll Free)

Osteonecrosis - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 37 Pages

Osteonecrosis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Pipeline Review, H2 2017, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline landscape.

Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist and ankle. Osteonecrosis can be caused by disease, or a severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. Symptomatic treatment is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteonecrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteonecrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteonecrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.

Osteonecrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteonecrosis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteonecrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteonecrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteonecrosis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteonecrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Osteonecrosis - Overview 5
Osteonecrosis - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Osteonecrosis - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 10
Assessment by Route of Administration 11
Assessment by Molecule Type 13
Osteonecrosis - Companies Involved in Therapeutics Development 15
Bone Therapeutics SA 15
Enzo Biochem Inc 15
K-Stemcell Co Ltd 16
Osteonecrosis - Drug Profiles 17
ALLOB - Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
LWnt-3a - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
PREOB - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology, Oncology and Cardiovascular Disease - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Osteonecrosis - Dormant Projects 29
Osteonecrosis - Product Development Milestones 30
Featured News & Press Releases 30
Jun 08, 2017: Bone Therapeutics: completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB 30
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study 30
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial 31
Jun 08, 2016: Bone Therapeutics demonstrates superiority of PREOB in Phase IIB osteonecrosis study presented at EULAR 31
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study 32
Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB 33
Nov 07, 2013: Bone Therapeutics' pivotal phase III osteonecrosis trial with PREOB hits a new milestone 33
Jan 28, 2013: Bone Therapeutics Raises 1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy 34
Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables
Number of Products under Development for Osteonecrosis, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 9
Number of Products by Stage and Mechanism of Action, H2 2017 10
Number of Products by Stage and Route of Administration, H2 2017 12
Number of Products by Stage and Molecule Type, H2 2017 14
Osteonecrosis - Pipeline by Bone Therapeutics SA, H2 2017 15
Osteonecrosis - Pipeline by Enzo Biochem Inc, H2 2017 15
Osteonecrosis - Pipeline by K-Stemcell Co Ltd, H2 2017 16
Osteonecrosis - Dormant Projects, H2 2017 29

List of Figures
Number of Products under Development for Osteonecrosis, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products by Routes of Administration, H2 2017 11
Number of Products by Stage and Routes of Administration, H2 2017 11
Number of Products by Molecule Types, H2 2017 13
Number of Products by Stage and Molecule Types, H2 2017 13

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *